Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Performing risk stratification for COVID-19 when individual level data is not available – the experience of a large healthcare organization

View ORCID ProfileNoam Barda, Dan Riesel, Amichay Akriv, Joseph Levi, Uriah Finkel, Gal Yona, Daniel Greenfeld, Shimon Sheiba, Jonathan Somer, Eitan Bachmat, Guy N. Rothblum, Uri Shalit, Doron Netzer, Ran Balicer, View ORCID ProfileNoa Dagan
doi: https://doi.org/10.1101/2020.04.23.20076976
Noam Barda
1Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
2School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Be’er Sheva, Israel
3Department of Computer Science, Ben Gurion University of the Negev, Be’er Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Noam Barda
Dan Riesel
1Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amichay Akriv
1Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Levi
1Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uriah Finkel
1Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gal Yona
4Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Greenfeld
5Faculty of Industrial Engineering and Management, Technion University, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shimon Sheiba
5Faculty of Industrial Engineering and Management, Technion University, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Somer
5Faculty of Industrial Engineering and Management, Technion University, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eitan Bachmat
3Department of Computer Science, Ben Gurion University of the Negev, Be’er Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy N. Rothblum
4Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uri Shalit
5Faculty of Industrial Engineering and Management, Technion University, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doron Netzer
6Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran Balicer
1Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
2School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Be’er Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noa Dagan
1Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
2School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Be’er Sheva, Israel
3Department of Computer Science, Ben Gurion University of the Negev, Be’er Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Noa Dagan
  • For correspondence: noada@clalit.org.il
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

With the global coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need for risk stratification tools to support prevention and treatment decisions. The Centers for Disease Control and Prevention (CDC) listed several criteria that define high-risk individuals, but multivariable prediction models may allow for a more accurate and granular risk evaluation. In the early days of the pandemic, when individual level data required for training prediction models was not available, a large healthcare organization developed a prediction model for supporting its COVID-19 policy using a hybrid strategy. The model was constructed on a baseline predictor to rank patients according to their risk for severe respiratory infection or sepsis (trained using over one-million patient records) and was then post-processed to calibrate the predictions to reported COVID-19 case fatality rates. Since its deployment in mid-March, this predictor was integrated into many decision-processes in the organization that involved allocating limited resources. With the accumulation of enough COVID-19 patients, the predictor was validated for its accuracy in predicting COVID-19 mortality among all COVID-19 cases in the organization (3,176, 3.1% death rate). The predictor was found to have good discrimination, with an area under the receiver-operating characteristics curve of 0.942. Calibration was also good, with a marked improvement compared to the calibration of the baseline model when evaluated for the COVID-19 mortality outcome. While the CDC criteria identify 41% of the population as high-risk with a resulting sensitivity of 97%, a 5% absolute risk cutoff by the model tags only 14% to be at high-risk while still achieving a sensitivity of 90%. To summarize, we found that even in the midst of a pandemic, shrouded in epidemiologic “fog of war” and with no individual level data, it was possible to provide a useful predictor with good discrimination and calibration.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

G.N.R. reports grants from Israel Science Foundation, grants from Israel-US Binational Science Foundation, grants from European Research Council, grants from Amazon Research Award during the conduct of the study. U.S. reports personal fees from K-health, outside the submitted work.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data availability Access to the data used for this study can be made available upon request, subject to an internal review by N.B. and N.D. to ensure that participant privacy is protected, and subject to completion of a data sharing agreement, approval from the institutional review board of Clalit Health Services and institutional guidelines and in accordance with the current data sharing guidelines of Clalit Health Services and Israeli law. Pending the aforementioned approvals, data sharing will be made in a secure setting, on a per-case-specific manner, as defined by the chief information security officer of Clalit Health Services. Please submit such requests to N.D. (noada@clalit.org.il). Code availability The analytic code required to produce the COVID-19 model predictions is available at: https://github.com/clalitresearch/COVID-19-Model

https://github.com/clalitresearch/COVID-19-Model

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 28, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Performing risk stratification for COVID-19 when individual level data is not available – the experience of a large healthcare organization
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Performing risk stratification for COVID-19 when individual level data is not available – the experience of a large healthcare organization
Noam Barda, Dan Riesel, Amichay Akriv, Joseph Levi, Uriah Finkel, Gal Yona, Daniel Greenfeld, Shimon Sheiba, Jonathan Somer, Eitan Bachmat, Guy N. Rothblum, Uri Shalit, Doron Netzer, Ran Balicer, Noa Dagan
medRxiv 2020.04.23.20076976; doi: https://doi.org/10.1101/2020.04.23.20076976
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Performing risk stratification for COVID-19 when individual level data is not available – the experience of a large healthcare organization
Noam Barda, Dan Riesel, Amichay Akriv, Joseph Levi, Uriah Finkel, Gal Yona, Daniel Greenfeld, Shimon Sheiba, Jonathan Somer, Eitan Bachmat, Guy N. Rothblum, Uri Shalit, Doron Netzer, Ran Balicer, Noa Dagan
medRxiv 2020.04.23.20076976; doi: https://doi.org/10.1101/2020.04.23.20076976

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4810)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5280)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (110)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (127)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (768)
  • Public and Global Health (1798)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (68)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)